Gyre Therapeutics appointed Yue Xiong, Ph.D., Maxwell Kirkby and Claire Weston, Ph.D. to its Board effective August 1, 2026.
| IndividualYue Xiong, Ph.D.Maxwell KirkbyClaire Weston, Ph.D. | RoleClass I director; also serves as Chief Scientific OfficerClass II director; member of the Compensation CommitteeClass III director; member of the Audit Committee | Type of ChangeAppointedAppointedAppointed | Effective DateAugust 1, 2026August 1, 2026August 1, 2026 | ReasonNot disclosedNot disclosedNot disclosed | Replacement InfoNot disclosedNot disclosedNot disclosed | Background DetailsPreviously entered into Company's indemnification agreement when appointed Chief Scientific OfficerTo receive initial grant of options for 40,000 shares (vesting monthly over 3 years); entitled to cash compensation per non-employee director policy; entering standard indemnification agreementTo receive initial grant of options for 40,000 shares (vesting monthly over 3 years); entitled to cash compensation per non-employee director policy; entering standard indemnification agreement | Board/Committee Role ChangesNot disclosedAppointed to Compensation CommitteeAppointed to Audit Committee |
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.